Top Markets
Coin of the day
Lisata Therapeutics, Inc. Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc.

LSTA
Kedudukan dalam Saham #32451
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on... Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Harga Saham
$1.11
Modal Pasaran
$10.06M
Perubahan (1 hari)
1.38%
Perubahan (1 tahun)
-56.32%
Negara
US
Perdagangan Lisata Therapeutics, Inc. (LSTA)

Kategori

Sejarah harga saham bagi Lisata Therapeutics, Inc. (LSTA)
Harga penutupan tertinggi: $1.12 pada 2026-08-01

Harga penutupan terendah: $188.93K pada 1999-03-01
Sejarah harga saham Lisata Therapeutics, Inc. dari 1999 hingga 2026
Prestasi harga saham tahunan
Tahun Prestasi
2026 (TTM) 52.31%
2025 -28.03%
2024 3.05%
2023 -6.25%
2022 -78.23%
2021 -42.33%
2020 -36.52%
2019 -44.38%
2018 26.19%
2017 2.72%
2016 -70.04%
2015 -68.59%
2014 -44.74%
2013 2.99%
2012 11.54%
2011 -61.50%
2010 -9.12%
2009 147.46%
2008 -61.79%
2007 -75.15%
2006 19.82%
2005 -7.65%
2004 -69.11%
2003 253.51%
2002 -86.70%
2001 -26.92%
2000 -63.97%
1999 0.00%
Harga saham bagi syarikat atau pesaing serupa
Syarikat Harga saham Perubahan 1thn% Negara
$515.58 32.24%
US
$992.01 50.00%
NL
$736.64 6.99%
CH
$1.07K -6.01%
KR
$255.50 12.02%
BE